

# INTERMOLECULAR INC

## **FORM 8-K** (Current report filing)

Filed 11/02/17 for the Period Ending 10/31/17

Address	3011 NORTH FIRST STREET SAN JOSE, CA, 95134
Telephone	(408) 582-5700
CIK	0001311241
Symbol	IMI
SIC Code	3674 - Semiconductors and Related Devices
Industry	Semiconductors
Sector	Technology
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
Form 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **October 31, 2017**

**Intermolecular, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35348**  
(Commission  
File Number)

**20-1616267**  
(IRS Employer  
Identification No.)

**3011 N. First Street**  
**San Jose, California**  
(Address of Principal Executive Offices)

**95134**  
(Zip Code)

**(408) 582-5700**  
(Registrant's Telephone Number, Including Area Code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS**

On October 31, 2017, the Compensation Committee of the Board of Directors of Intermolecular, Inc. (the “Company”) approved increases in the annual base salaries of Christian F. Kramer, President and Chief Executive Officer, and Bill Roeschlein, Chief Financial Officer, with such changes to be effective as of January 1, 2018 subject to the satisfaction of certain conditions related to the Company’s financial performance.

The annual base salaries for Mr. Kramer and Mr. Roeschlein for 2018, assuming satisfaction of the specified financial performance conditions, are set forth below:

<u>Name</u>	<u>Title</u>	<u>2018 Base Salary</u>
Christian F. Kramer	President and Chief Executive Officer	\$ 446,250
Bill Roeschlein	Chief Financial Officer	\$ 283,500

The Company will provide additional information regarding the compensation paid to the named executive officers for fiscal year 2017 in its definitive proxy statement for the 2017 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission in the second quarter of 2018.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERMOLECULAR, INC.

Date: November 02, 2017

By: \_\_\_\_\_ /s/ Bill Roeschlein  
Bill Roeschlein  
Chief Financial Officer

---